secwatch.observer — SEC 8-K summary
======================================

Issuer:     IRIDEX CORP (IRIX)
CIK:        0001006045
Form:       8-K
Filed at:   2024-11-12T23:59:59+00:00
Accession:  0000950170-24-125464
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Iridex Q3 revenue $11.6M (-10% YoY); net loss $1.9M; expects EBITDA breakeven in Q4
--------------------------------------------------------------------------------

- Total revenue $11.6M, down 10% YoY; retina revenue $6.5M (-18% YoY).
- Cyclo G6 glaucoma revenue $3.1M (+3% YoY) with 13,600 probes sold.
- Net loss $1.9M ($0.12/sh) vs $1.8M loss ($0.11/sh) in Q3'23; gross margin 37.3% vs 43.7%.
- Appointed Patrick Mercer as CEO (effective Oct 1, 2024); strategic review ongoing with multiple parties.
- New Medicare LCDs effective Nov 17, 2024 expected to boost glaucoma product adoption.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1006045/000095017024125464/0000950170-24-125464-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1006045/000095017024125464/irix-20241112.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-125464

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer